Rivaroxaban vs Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease

Phase 4, randomised, open-label trial of rivaroxaban in Kawasaki disease (KD) and coronary artery aneurysm (CAA) (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Composite of new thrombosis in coronary arteries, major bleeding, clinically relevant non-major bleeding event or major adverse cardiovascular event at 3 months. Started Jun 2025; status: recruiting.